748 related articles for article (PubMed ID: 30210004)
1. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
2. Searching for Potential Novel BCR-ABL Tyrosine Kinase Inhibitors Through G-QSAR and Docking Studies of Some Novel 2-Phenazinamine Derivatives.
Kale M; Sonwane G; Choudhari Y
Curr Comput Aided Drug Des; 2020; 16(5):501-510. PubMed ID: 30345925
[TBL] [Abstract][Full Text] [Related]
3. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
Melge AR; Kumar LG; K P; Nair SV; K M; C GM
J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
[TBL] [Abstract][Full Text] [Related]
5. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
6. Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Vrontaki E; Melagraki G; Voskou S; Phylactides MS; Mavromoustakos T; Kleanthous M; Afantitis A
Mini Rev Med Chem; 2017; 17(3):188-204. PubMed ID: 28143387
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of pyridin-3-yl pyrimidines as potent Bcr-Abl inhibitors.
Pan X; Dong J; Gao H; Wang F; Zhang Y; Wang S; Zhang J
Chem Biol Drug Des; 2014 May; 83(5):592-9. PubMed ID: 24330598
[TBL] [Abstract][Full Text] [Related]
9. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
10. In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase.
Koroleva EV; Kornoushenko YV; Karpenko AD; Bosko IP; Siniutsich JV; Ignatovich ZV; Andrianov AM
J Biomol Struct Dyn; 2023 Jun; 41(9):4065-4080. PubMed ID: 35470777
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
Hu L; Zheng Y; Li Z; Wang Y; Lv Y; Qin X; Zeng C
Bioorg Med Chem; 2015 Jul; 23(13):3147-52. PubMed ID: 26022079
[TBL] [Abstract][Full Text] [Related]
12. Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone.
Khan T; Ahmad R; Azad I; Raza S; Joshi S; Khan AR
Comput Biol Chem; 2018 Aug; 75():178-195. PubMed ID: 29883916
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological activities of Nilotinib derivates as antitumor agents.
Pan X; Wang F; Zhang Y; Gao H; Hu Z; Wang S; Zhang J
Bioorg Med Chem; 2013 May; 21(9):2527-34. PubMed ID: 23538233
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel Bcr-Abl
Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J
Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413
[TBL] [Abstract][Full Text] [Related]
15. Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
Shan Y; Dong J; Pan X; Zhang L; Zhang J; Dong Y; Wang M
Eur J Med Chem; 2015 Nov; 104():139-47. PubMed ID: 26451772
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules.
Cao R; Wang Y; Huang N
J Chem Inf Model; 2015 Nov; 55(11):2435-42. PubMed ID: 26501568
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
Hu L; Cao T; Lv Y; Ding Y; Yang L; Zhang Q; Guo M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5830-5835. PubMed ID: 28029512
[TBL] [Abstract][Full Text] [Related]
18. vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain.
Metibemu DS; Oyeneyin OE; Metibemu AO; Adeniran OY; Omotuyi IO
Curr Drug Discov Technol; 2022; 19(2):e021221198480. PubMed ID: 34856909
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.
Shibata N; Shimokawa K; Nagai K; Ohoka N; Hattori T; Miyamoto N; Ujikawa O; Sameshima T; Nara H; Cho N; Naito M
Sci Rep; 2018 Sep; 8(1):13549. PubMed ID: 30202081
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and anticancer activity of some novel 2-phenazinamine derivatives.
Gao X; Lu Y; Fang L; Fang X; Xing Y; Gou S; Xi T
Eur J Med Chem; 2013 Nov; 69():1-9. PubMed ID: 23995213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]